Results 71 to 80 of about 6,789 (241)

Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies [PDF]

, 2019
Background: The heterogeneity of histological findings in preclinical diet-induced nonalcoholic fatty liver disease (NAFLD) animal models is highly challenging.
���������
core   +1 more source

Imaging of Lipid Droplets in Living Cells and Mice with Metabolic Dysfunction‐Associated Steatotic Liver Disease via a Galactose‐Modified Supramolecular Near‐Infrared Fluorescent Glycoprobe

Advanced Functional Materials, Volume 36, Issue 3, 8 January 2026.
A galactose‐modified supramolecular near‐infrared (NIR) glycoprobe, TCF‐FBN@Gal‐BSA, enables targeted delivery to the liver through the asialoglycoprotein receptor (ASGPR) and facilitates liver‐targeting fluorescence visualization of lipid droplets (LDs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) mice.
Han‐Min Wang, Lei Dong, Qiu‐Lian Hao, Lu‐Lu Sun, Xin‐Rong Li, Yu‐Wei Yuan, Ming‐Ye Tang, Jin Gong, Yi Zang, Jia Li, Tony D. James, Xiao‐Peng He, Hai‐Hao Han   +12 more
wiley   +1 more source

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease

Drug Design, Development and Therapy, 2019
Dan-Ying Zhang,1,* Lin Zhu,2,* Hai-Ning Liu,1,* Yu-Jen Tseng,3 Shu-Qiang Weng,1 Tao-Tao Liu,1 Ling Dong,1 Xi-Zhong Shen1,41Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, People’s Republic of China ...
Zhang DY, Zhu L, Liu HN, Tseng YJ, Weng SQ, Liu TT, Dong L, Shen XZ   +7 more
doaj  

Vitamin D to reduce liver fibrosis in non-alcoholic fatty liver disease [PDF]

, 2017
BACKGROUND: As the prevalence of metabolic risk factors in the American population has increased over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD).
Fox, Ryan
core  

Bile Acids as Key Mediators of the Gut Microbiota–Immune Axis: Potential Biomarker and Therapeutic Perspectives

BioFactors, Volume 52, Issue 1, January/February 2026.
Primary bile acids synthesized in the liver are transformed by gut microbes into secondary bile acids that engage receptors such as FXR and TGR5, thereby modulating immune function and metabolic homeostasis. Dysregulation of these signaling pathways contributes to MASH, NAFLD, IBD, and neurodegenerative disorders, underscoring their relevance as ...
Simone Baldi, Margherita Turrini, Francesco Cei, Marta Menicatti, Gianluca Bartolucci, Amedeo Amedei   +5 more
wiley   +1 more source

Update on Emerging Treatment Options for Primary Biliary Cholangitis

Hepatic Medicine: Evidence and Research, 2020
Maria T Aguilar,1 David M Chascsa2 1Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; 2Department of Gastroenterology & Hepatology, Mayo Clinic, Phoenix, AZ, USACorrespondence: Maria T Aguilar Email aguilar.maria1 ...
Aguilar MT, Chascsa DM
doaj  

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases

Frontiers in Pharmacology, 2020
Cardiometabolic diseases are characterized as a combination of multiple risk factors for cardiovascular disease (CVD) and metabolic diseases including diabetes mellitus and dyslipidemia.
Chao Li, Jie Yang, Yu Wang, Yingzi Qi, Wenqing Yang, Yunlun Li, Yunlun Li   +6 more
doaj   +1 more source

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis [PDF]

, 2019
BACKGROUND: The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH).
Adams, Aithal, Andrade, Angulo, Armstrong, Arroyo, Athyros, Avigan, Banderas, Bays, Belfort, Bjornsson, Caldwell, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Cusi, De Denus, De Santis, Dutta, Eijgenraam, Ekstedt, Ekstedt, European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), Fontana, Friedman, Friedman, Giannini, Guha, Hayashi, Hoofnagle, Hyysalo, Im, Jalan, Kaplan, Kleiner, Kleiner, Kolwankar, Kowdley, Kullak-Ublick, Kwok, LaBrecque, Lavine, Lewis, Lewis, Liddle, Lo Re, Loomba, Maurice, McPherson, Moylan, Mudaliar, Neuschwander-Tetri, Panteghini, Pantsari, Patel, Patel, Pfeffer, Ratziu, Ratziu, Regev, Reid, Robles-Diaz, Rockstroh, Russo, Sanyal, Sanyal, Sanyal, Scorletti, Senior, Siddiqui, Stefan, Tarantino, Temple, Valenti, Verna, Vilar-Gomez, Vuppalanchi, Vuppalanchi, Vuppalanchi, Watkins, Weltman, Wong, Younossi, Younossi, Zelber-Sagi, Zhou, Zimmerman   +91 more
core   +1 more source

Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects

ChemMedChem, Volume 21, Issue 2, January 2026.
Novel obeticholic acid derivatives were designed and synthesized through targeted structural modifications at the C3α position and side chain. Valine analogs act as selective FXR partial agonists with favorable metabolic stability and no cytotoxicity, providing safer chemical tools for developing FXR modulators with reduced side effects such as ...
Daniela Passeri, Bruno Cerra, Andrea Carotti, Francesco Greco, Sara Piermarini, Carolina Colliva, Paride Liscio, Francesca De Franco, Luciano Adorini, Mary Ruth Erickson, Roberto Pellicciari, Antimo Gioiello   +11 more
wiley   +1 more source

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment

BMC Gastroenterology
Background Ursodeoxycholic acid is the preferred first-line therapy for primary biliary cholangitis. Alternative therapies, such as obeticholic acid, are recommended for patients who cannot tolerate ursodeoxycholic acid or who have an inadequate response
Nicholas MacDonald, Rebecca Loh, Jonathan M. Fenkel, David A. Sass, Dina Halegoua-DeMarzio   +4 more
doaj   +1 more source